Those manufacturers can then sell those medicines at much lower cost to people who need access to them, to treatment programs that need access to them.
Esas manufactureras pueden vender esas medicinas a más bajo costo a personas que necesitan acceder a ellas para programas de tratamiento que necesitan acceder a ellas.